title: Building bridges and providing transparency to the hepatitis C virus drug approval process.
authors.affiliation: National Institutes of Health, Bethesda, Maryland.
authors.forename: Marc G
authors.initials: MG
authors.lastname: Ghany
authors.affiliation: National Institutes of Health, Bethesda, Maryland.
authors.forename: T Jake
authors.initials: TJ
authors.lastname: Liang
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000069474:Sofosbuvir; D014481:United States; D014486:United States Food and Drug Administration; D014542:Uridine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D014542:Uridine Monophosphate; D000069474:Sofosbuvir